Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (2026)	3/17/1999 11:14:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

You seem to be reading the report as a single $10-15B buy. I am not saying they are interested in SEPR, but look at the attributes they are looking for, refilling their pipeline appears to be real high, if not #1. I read Abbott's the intent as multiple buys, and they need an ample pipeline contribution. Again I'm not selling, in fact I want to hang in there for my reward. However, SEPR offers lower than normal costs and schedule to capitalize on their disproportionately large pipeline.